Benjamin Halladay serves as the Chief Financial Officer at Esperion Therapeutics Inc., a pharmaceutical company focused on developing and commercializing innovative therapies for the treatment of elevated levels of low-density lipoprotein cholesterol (LDL-C). In his role at Esperion, Halladay is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, and investor relations. His strategic financial leadership has been instrumental in guiding Esperion through its growth phases, particularly as the company advances its pipeline of novel lipid management therapies. Prior to joining Esperion, Halladay amassed extensive experience in the biopharmaceutical industry, holding key financial positions at several notable companies. He previously served as CFO at Tetraphase Pharmaceuticals, where he played a pivotal role in the company's successful IPO and subsequent growth. Before Tetraphase, Halladay held senior finance roles at Cubist Pharmaceuticals and Genzyme Corporation, where he honed his skills in financial strategy and corporate development. His background also includes time at Ernst & Young, where he developed a strong foundation in financial auditing and advisory services. Halladay's diverse experience and proven track record in the life sciences sector have made him a valuable asset to Esperion as the company continues to expand its reach and impact in the cardiovascular health market.